Veteran Microsoft Executive and Distinguished Engineer, Sean Nolan, joins Adaptive Biotechnologies as Chief Technology Officer

Sean_Nolan1

Adaptive is pleased to announce the appointment of Sean Nolan as Chief Technology Officer and the newest member of the Company’s expanding Executive Leadership Team.  Mr. Nolan’s hire, the second management hire this month, represents Adaptive’s continued commitment to incorporating state-of-the-art data solutions into its suite of immunosequencing products and services.

Adaptive in Seattle Times

home-news

Adaptive Biotechnologies, a Seattle startup that focuses on scouring the genetic makeup of the immune system to help fight cancer and other diseases, said Monday it has raised an eye-popping $105 million in funding to boost its research and commercial efforts. Read full article at Times Website

Adaptive Biotechnologies Announces Completion of Series C and Series D Financing Rounds Through a $105 million Private Investment from Viking Global Investors

Original Founders of Adaptive

Adaptive announced today the completion of the Company’s Series C financing round and the completion of a newly created Series D round with a $105 million investment from Viking Global Investors.  This investment will enable the Company to expand globally its preeminent immunosequencing research platform and downstream validated clinical diagnostic products.